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 2 
Abstract 1 
The cotton bollworm P450s of the clustered CYP6AE subfamily share high sequence identities 2 
but differ dramatically in their capacity to metabolize xenobiotics, especially esfenvalerate. 3 
Among them, CYP6AE17 has the highest sequence identity with CYP6AE18 but shows ~7-4 
fold higher metabolic efficiency. CYP6AE11 is most active towards esfenvalerate but 5 
CYP6AE20 is inactive even though the enzymes share 54.8% sequence identity. Sequence 6 
analysis revealed the SRS1 (Substrate Recognition Site) and SRS6 between CYP6AE17 and 7 
CYP6AE18, and SRS1 between CYP6AE11 and CYP6AE20 are the most variable among all 8 
six SRSs. In order to identify the key factors that underlie the observed catalytic difference, we 9 
exchanged these SRS sequences between two pairs of P450s and studied the activity of the 10 
resulting hybrid mutants or chimeras. In vitro metabolism showed that the CYP6AE17/18 11 
chimeras had 2- and 10-fold decreased activities and the CYP6AE18/17 chimeras had 6- and 12 
10-fold increased activities to esfenvalerate. Meanwhile, after exchanging SRS1 with each other, 13 
the CYP6AE11/20 chimera folded incorrectly but the CYP6AE20/11 chimera gained moderate 14 
activity to esfenvalerate. Molecular modeling showed that amino acids variants within SRS1 or 15 
SRS6 change the shape and chemical environment of the active sites, which may affect the 16 
ligand-binding interactions. These results indicate that the protein structure variation resulting 17 
from the sequence diversity of SRSs promotes the evolution of insect chemical defense and 18 
contributes to the development of insect resistance to pesticides.  19 
 20 
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Metabolism; Molecular modeling  22 
 3 
1. Introduction 1 
The cotton bollworm, Helicoverpa armigera (Hübner), is a global generalist pest that is 2 
distributed throughout Europe, Africa, Asia, and South America on over 300 different plant 3 
hosts (Tay et al., 2013). Broad host range and wide distribution of this pest lead to increased 4 
exposure to different kinds of environmental toxins and to a greater capacity to cope with 5 
variable environments (Dermauw et al., 2018). To date, under high selection pressure of 6 
pesticides, resistance cases to most insecticide classes and Bt toxins have been reported for this 7 
insect (www.pesticideresistance.org). Cytochrome P450-based detoxification was confirmed as 8 
one of the most crucial resistance mechanisms within most geographical populations of H. 9 
armigera (Joußen et al., 2012; Oakeshott et al., 2013; Rasool et al., 2014; Yang et al., 2004, 10 
2005, 2006). 11 
Cytochrome P450 monooxygenases (P450s) are an important superfamily of hemoproteins, 12 
found in almost all organisms, which participate in the biosynthesis and metabolism of 13 
endogenous compounds and the detoxification of xenobiotics (Feyereisen, 2012). P450s play a 14 
crucial role in the survival of insects. In addition to being intermediates in basal physiological 15 
metabolism, most insect P450s are involved in the detoxification of insecticides and 16 
phytochemicals. The catalytic capability and efficiency of P450s are determined by structure, 17 
especially the amino acids that determine the shape and size of the active site. Analyses of 18 
available mammalian and microbial P450 structures revealed that the overall three-dimensional 19 
structures of P450s are conserved despite an often low amino acid sequence identity (Feyereisen, 20 
2012; Guengerich et al., 2016). Comparisons of primary sequences have suggested that six 21 
substrate recognition sites (SRSs) with highly variable sequences account for the diverse range 22 
of the substrate specificities of P450s (Gotoh, 1992). Extensive site-directed mutagenesis 23 
studies have shown that SRSs constitute several important domains within the tertiary structure 24 
of P450 proteins and contribute to function (Chen et al., 2002; Paine et al., 2003; Pan et al., 25 
2004). The P450 catalytic site is mainly determined by SRS1, SRS4, SRS5 and SRS6 and the 26 
substrate access channel is shaped mainly by SRS2 and SRS3 (Schuler et al., 2013). While it is 27 
clear that the SRSs play significant roles in defining enzyme activity and substrate ranges in 28 
various bacterial, mammalian and insect P450s, our understanding of relationships between 29 
SRS sequences and enzyme properties remains poor. For example, many closely-related P450s 30 
 4 
display differences in substrate metabolism whereas phylogenetically distinct P450s may 1 
metabolize similar substrates (Rupasinghe et al., 2007; Wang et al., 2018). Nevertheless, the 2 
variations of P450 activities or substrate profiles mediated by SRS can reveal the evolution and 3 
divergence of P450 orthologs or paralogs (Dueholm et al., 2015; Li et al., 2003; Wen et al., 4 
2006). 5 
A typical “bloom” of CYP genes (Feyereisen, 2011), the CYP6AE subfamily has expanded 6 
in several lepidopteran insects (Calla et al., 2017; Shi et al., 2018). It is one of the principal 7 
P450 subfamilies responsible for the ability of H. armigera larvae to detoxify xenobiotics 8 
(Krempl et al., 2016; Shi et al., 2018; Wang et al., 2018). Many CYP6AE are constitutively 9 
overexpressed in pyrethroid resistant H. armigera strains (Barale et al., 2010; Rasool et al., 10 
2014) and over half the members of the CYP6AE subfamily in H. armigera are transcriptionally 11 
sensitive to over ten kinds of plant allelochemicals and synthetic compounds (Celorio-Mancera 12 
et al., 2011; Krempl et al., 2016; Mao et al., 2007; Tao et al., 2012; Zhang et al., 2016; Zhou et 13 
al., 2010; Pearce et al., 2017). Complete in vivo and in vitro tests provided direct evidence that 14 
CYP6AEs are involved in the detoxification of xanthotoxin, 2-tridecanone, esfenvalerate, 15 
indoxacarb, imidacloprid and aldrin (Shi et al., 2018; Wang et al., 2018), thus showing that they 16 
play a crucial role in the chemical defense of H. armigera. Ten CYP6AE subfamily members 17 
share high amino acid sequence identities (up to 91.8%) but exhibit great variation in metabolic 18 
activities. In particular, in vitro metabolism of esfenvalerate revealed a greater than 40-fold 19 
efficiency difference between CYP6AE11/14 and CYP6AE19/20 clades which share ~55% 20 
sequence similarity; CYP6AE20 even lacked metabolic capacity toward this pyrethroid. In 21 
addition, the Vmax of CYP6AE17 was 15-fold higher than CYP6AE18 resulting in a ~7-fold 22 
efficiency difference despite the fact that they share 91.8% sequence identity (Shi et al., 2018). 23 
We hypothesize that sequence variants within the SRS regions are major determinants of the 24 
large metabolic differences observed in this CYP6AE subfamily.  25 
In this study, we analyzed the sequences of two distinctive CYP6AE P450 pairs: 26 
CYP6AE11-CYP6AE20 and CYP6AE17-CYP6AE18. Six CYP6AE sequence hybrids of 27 
chimeras were generated by exchanging the SRS1 and SRS6 sections of the parent sequences, 28 
as these were shown to be the most variable SRS regions. The metabolic activities of wild-type 29 
and mutant CYP6AE enzymes were determined using esfenvalerate as the substrate. Molecular 30 
 5 
modelling was also performed to identify amino acids that may contribute to ligand-binding 1 
interactions.  2 
 3 
2. Materials and methods 4 
2.1 Reagents and Chemicals 5 
Enzymes for DNA fragment cloning (Q5 High-Fidelity DNA Polymerase), digestion 6 
(restriction enzymes) and linkage (T4 ligase) were supplied by New England Biolabs Company 7 
(Ipswich, MA). Esfenvalerate was purchased from Dr. Ehrentsorfer GmbH (Augsburg, 8 
Germany). HPLC solvents were purchased from Fisher Scientific (Pittsburgh, Pennsylvania). 9 
 10 
2.2 Construction and functional expression of P450 hybrid mutants  11 
The wild-type CYP6AE11, CYP6AE20, CYP6AE17 and CYP6AE18 were previously 12 
subcloned into pFastBacHTA (Shi et al., 2018). The mutants were constructed by fusion PCR. 13 
SRS1 or SRS6 and their flanking sequences with overlap sequence were cloned separately. Two 14 
flanking sequences and target SRS sequence were linked by a second round of PCR with full-15 
length primers (Fig. S1). The primers used for cloning are shown in Table S1. All mutants were 16 
cloned into pFastBacHTA vector (Invitrogen). The baculovirus plasmid was produced and 17 
transfected into Sf9 cells according to the Bac-to-Bac baculovirus expression system 18 
(Invitrogen) as described (Shi et al., 2018). The P450 mutants and non-insertion control were 19 
coexpressed with H. armigera cytochrome P450 reductase (HaCPR) in High Five cells 20 
(Invitrogen); the multiplicity of infection (MOI) of P450 and HaCPR was 2 and 0.2, respectively. 21 
Microsomes were purified by differential centrifugation. The recombinant P450 was identified 22 
by Western blot with 6×His tag antibody (Abcam, Cambridge, UK) and quantified by reduced 23 
CO-difference spectra assay (Omura et al., 1964).  24 
 25 
2.3 Esfenvalerate metabolism and UPLC-MS/MS analysis 26 
    The metabolism of esfenvalerate was performed with 0.1mg microsomes containing 27 
recombinant P450 or non-insertion control. The in vitro metabolism system was incubated in 28 
200 μl 0.1 M potassium phosphate buffer (pH 7.4) in 1.5 ml Eppendorf tube with an NADPH-29 
regenerating system (1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2 and 0.4 30 
 6 
U/mL glucose-6-phosphate dehydrogenase) and 1μl esfenvalerate (5 μM, freshly dissolved in 1 
acetonitrile). Reactions were pre-warmed in 30 oC for 5 min and started after adding insecticide. 2 
Samples were incubated at 30 oC, 1,200 rpm for 1h and reactions were stopped by adding 200 3 
μl acetonitrile and incubating for a further 20 min. Samples were centrifuged at 18,000×g for 4 
15min before being transferred to HPLC vials and analyzed immediately by tandem mass 5 
spectrometry as described (Shi et al., 2018). Samples without NADPH were performed at the 6 
same time. The final metabolic activity was corrected by subtracting the background (non-7 
insertion control) and expressed as pmol 4’-hydroxy-metabolite per minute per mg protein. For 8 
the kinetic assay, 10 pmol P450 was used in each sample and suitable ranges of substrate 9 
concentrations for each P450 were performed after several pre-tests. 10 
 11 
2.4 Homology modelling and automated ligand docking 12 
Chain A of the human cytochrome P450 CYP3A5 X-ray crystal structure (PDB code 13 
5VEU) (Hsu et al., 2018) provided the template for homology modelling of the CYP6AE11, 14 
CYP6AE20, CYP6AE17 and CYP6AE18 enzymes. A multiple sequence alignment was 15 
performed using Clustal Omega (Sievers et al., 2011). Each homology model was generated 16 
using MODELLER (Eswar et al., 2006) to produce 50 starting models. The internal scoring 17 
function of MODELLER was used to select 10 models that were visually inspected and 18 
submitted to the VADAR webserver (Willard et al., 2003) for assessment of stereochemical 19 
soundness, with the best model selected based on these structural evaluations.  20 
A structure for esfenvalerate was generated ab initio using MarvinSketch (version 5.9.1) 21 
of the ChemAxon suite (http://www.chemaxon.com). AutoDockTools (version 1.5.4) 22 
(Molecular Graphics Laboratory, Scripps Research Institute, La Jolla, CA, USA) was used to 23 
define rotatable bonds in esfenvalerate and merge the non-polar hydrogens. Automated ligand 24 
docking studies of esfenvalerate with CYP6AE homology models were performed using Auto-25 
Dock Vina (version 1.1.2) (Trott et al., 2010) with a grid of 40 × 40 × 40 points (1 Å spacing) 26 
centred on the enzyme’s central cavity. Docking predictions were screened by interaction 27 
energy and by selecting poses where the esfenvalerate phenoxyphenyl group was <4.5 Å 28 
distance from the enzyme heme group.  29 
The volume of each enzyme’s active site cavity was plotted using Caver3 (Chovancova et 30 
 7 
al., 2012) with a probe radius of 1.5 Å, shell radius of 3 Å and a shell depth of 4 Å. Figures 1 
were produced using PyMOL (DeLano Scientific, San Carlos, CA, USA). 2 
 3 
3 Results 4 
3.1 Amino acid sequence analysis of four CYP6AE P450 genes 5 
The sequences of CYP6AE11, CYP6AE20, CYP6AE17 and CYP6AE18 are shown in Fig. 6 
1. CYP6AE11 and CYP6AE20 have low sequence identities in SRS1, SRS3 and SRS6, and 7 
SRS1 shows the lowest identity between the two genes (fifteen substitutions with eleven 8 
nonsynonymous substitutions) (Table S2). CYP6AE17 shares high sequence identity with 9 
CYP6AE18 with the exception of SRS1 (five nonsynonymous substitutions) and SRS6 (four 10 
nonsynonymous substitutions). In order to explore the significance of these diverse SRSs in the 11 
metabolism of esfenvalerate, we exchanged SRS1 between CYP6AE11 and CYP6AE20 to 12 
create CYP6AE11-20SRS1 and CYP6AE20-11SRS1 chimeric enzymes. In addition, SRS1 and 13 
SRS6 were exchanged between CYP6AE17 and CYP6AE18 to create CYP6AE17-18SRS1, 14 
CYP6AE17-18SRS6, CYP6AE18-17SRS1 and CYP6AE18-17SRS6 (Fig. 2). 15 
 16 
3.2 Functional expression of six mutants in High Five cell line 17 
    The recombinant P450s and HaCPR in purified microsomes were identified by Western 18 
blot (Fig. 3A). The six chimeras migrated between 50-60kDa and HaCPR located near 75kDa 19 
as predicted. Reduced CO-difference spectrum of each individually expressed protein revealed 20 
that all generated CO-spectrum maxima near 450nm except CYP6AE11-20SRS1. A 21 
significantly high concentration of P420 could be detected in recombinant CYP6AE11-20SRS1 22 
but no peak could be found near 450nm under a variety of expression and detection conditions 23 
(Fig. 3B). 24 
 25 
3.3 Metabolism of esfenvalerate 26 
The results of in vitro metabolism revealed that all six P450 mutants could metabolize 27 
esfenvalerate because the formation of 4’-hydroxy-esfenvalerate in each sample was 28 
significantly higher than the non-insertion control incubated under the same conditions (Fig. 4).  29 
The 4’-hydroxy-esfenvalerate formation rates of each recombinant mutant in response to 30 
 8 
esfenvalerate concentration revealed Michaelis-Menten kinetics (Fig. S2). The metabolic 1 
capabilities of six mutants to esfenvalerate varied considerably (Table 1). Compared with wild-2 
type CYP6AE P450s, the chimera CYP6AE20-11SRS1 (CYP6AE20 with the SRS1 from 3 
CYP6AE11) gained a moderate ability (Vmax/Km) to metabolize esfenvalerate. CYP6AE11-4 
20SRS1 showed similar affinity (Km) to esfenvalerate as wild type. As no peak near 450 nm 5 
could be detected in the CO-difference spectrum of CYP6AE11-20SRS1, the concentration of 6 
recombinant P450 in the microsomal protein could not be measured accurately and so the final 7 
enzyme activity was corrected by mg protein. Meanwhile, the substitution of SRS1 had a great 8 
impact on CYP6AE17 as the Vmax of CYP6AE17-18SRS1 decreased ten-fold and ultimately 9 
resulted in a ~13-fold decrease in metabolic efficiency (Vmax/Km). In contrast, the exchange 10 
of SRS6 produced a lesser effect on CYP6AE17 with a ~2-fold decrease in both substrate 11 
affinity and metabolic efficiency for CYP6AE17-18SRS6 compared with wild-type 12 
CYP6AE17. On the other hand, the Vmax of CYP6AE18 increased 15-fold after the exchange 13 
of SRS1 from CYP6AE17 and, while the affinity decreased slightly, there was an overall ~6-14 
fold increase in metabolic efficiency. With regards the SRS6 region, the Vmax of CYP6AE18 15 
increased 7-fold when the 5 amino acids were substituted to their CYP6AE17 equivalents and 16 
there was a slight increase in affinity to esfenvalerate, which ultimately increased the efficiency 17 
(Vmax/Km) by an order of magnitude. 18 
 19 
3.4 Active site cavities and esfenvalerate binding interactions in CYP6AE models  20 
Homology models of the wild-type CYP6AE11, CYP6AE17, CYP6AE18 and CYP6AE20 21 
enzymes were generated based on the structure of the human cytochrome P450 CYP3A5 (Hsu 22 
et al., 2018). This template was chosen due to its high-resolution (2.91 Å) and its 28-29% 23 
sequence identity with the four H. armigera enzymes (Fig. S3). Analysis of the homology 24 
models identified a number of SRS1 and SRS6 residues that line the active site cavity and may 25 
therefore be positioned to make ligand-binding interactions (Fig. 5A).  26 
Fig. 5B shows the variation in the volumes of the active site cavities, with CYP6AE17 and 27 
CYP6AE18 having more voluminous cavities than CYP6AE11 and CYP6AE20. In particular, 28 
the aromatic side chain of SRS6 F496 (residues in all models are numbered according to the 29 
CYP6AE11 sequence to enable comparisons) projects into the CYP6AE11 and CYP6AE20 30 
 9 
cavities to constrict the active site. There is an additional aromatic side chain (F121) in the 1 
CYP6AE20 enzyme that projects into the cavity whereas this 121 position on SRS1 is occupied 2 
by the smaller side-chain alanine or serine in CYP6AE11, CYP6AE17 and CYP6AE18. 3 
Accordingly, a docking prediction of esfenvalerate and with an estimated -9.5 kcal/mol binding 4 
affinity shows the ligand folded in the tightly confined space of the CYP6AE20 cavity. In 5 
contrast esfenvalerate adopts a more elongated pose when occupying the active sites of 6 
CYP6AE11 (-9.1 kcal/mol), CYP6AE17 (-9.2 kcal/mol) and CYP6AE18 (-8.4 kcal/mol) (Fig. 7 
5B).  8 
The SRS1 109 residue is phenylalanine in CYP6AE17 but tyrosine in CYP6AE18 whereas 9 
the SRS6 496 residue is threonine in CYP6AE17 but isoleucine in CYP6AE18. The hydroxyl 10 
group of Y109 projects into the CYP6AE18 cavity as does the I496 side chain therefore 11 
presenting different chemical groups to the active site. Similarly, the SRS1 112 position is 12 
occupied by the small side-chain serine residue in CYP6AE20 but by a positively-charged 13 
amino acid in CYP6AE11, CYP6AE17 and CYP6AE18. The CYP6AE17 R112 side chain is 14 
4.8 Å from the esfenvalerate cyano-group nitrogen, the CYP6AE18 R112 side chain is 3.2 Å 15 
from the ligand’s carbonyl oxygen and the α-amino of the CYP6AE11 K112 side chain is 5.55 16 
Å from the ligand cyano nitrogen. As discussed below, the amino acid variants at these 17 
identified positions may underlie the different activities of the P450s towards esfenvalerate. 18 
 19 
4 Discussion 20 
In this study, we demonstrate using chimeric enzymes generated by fragment substitution 21 
that the SRS1 and SRS6 regions have a major impact on protein folding and metabolic 22 
capability of the CYP6AE enzymes. The metabolic efficiencies of mutants from CYP6AE17 23 
and CYP6AE18 changed significantly after exchange of their SRS1 or SRS6 sections. Most 24 
notable is the activity of the CYP6AE20-11SRS1 construct given the lack of metabolic activity 25 
of the wild-type CYP6AE20 towards esfenvalerate.  26 
To date, multiple site-directed mutagenesis studies have demonstrated that amino acids in 27 
SRSs affect the protein folding and substrate range of cytochrome P450s. Among the six SRS 28 
regions, the SRS1 in a loop region, close to the active site heme, has proven to be the most 29 
important SRS that affects multiple properties of P450s (Domanski et al., 2001; Graham-30 
 10 
Lorence et al., 1996; Schuler et al., 2013). In the CYP6B subfamily, several conserved amino 1 
acids in SRS1 and variable positions in SRS6 are proposed to form an aromatic-aromatic 2 
resonant network that maintains the hydrophobic catalytic pocket and determines substrate 3 
turnover/specificity (Baudry et al., 2003; Chen et al., 2002). Two variable amino acids, Ile115 4 
and A113, in the SRS1 of CYP6B subfamily proteins, form a hydrogen bond network that 5 
controls the spin state of the heme and effects the catalytic activity and substrate range (Pan et 6 
al., 2004). In H. armigera, there is an example of a natural chimera, CYP337B3, a gene 7 
conversion product (from unequal crossing-over) which consists of the partial N-terminal 8 
sequence with SRS1 from its paralog CYP337B2 and the C-terminal part of the other paralog 9 
CYP337B1. This new gene product can metabolize fenvalerate and cypermethrin while its 10 
originator paralogs cannot (Joußen et al., 2012; Rasool et al., 2014). In our study, it was also 11 
demonstrated that SRS1 and SRS6 regions affected the fenvalerate metabolism efficiency of H. 12 
armigera CYP6AE P450s. In addition, it has been reported that the formation of CO-difference 13 
maxima at 420nm might result from conformational changes that restricts substrate access and 14 
binding in the catalytic site (Martinis et al., 1996). In our study, CYP6AE11-20SRS1 formed 15 
no peak at 450nm but significant activity to esfenvalerate could nonetheless be detected in in 16 
vitro metabolism. Possibly this protein sample consisted of an abundance of P420 with a 17 
concentration of correctly-folded P450 that was too low to be detected by the reduced CO-18 
difference spectrum assay. Alternatively, the conformational change induced by substrate 19 
binding might restore a normal heme-thiolate environment.  20 
There are a number of mechanisms by which a change in a P450 sequence can result in 21 
altered function (Schuler et al., 2013). One mechanism is that the access channel gets reshaped, 22 
which subsequently affects substrate entry. Analysis of mosquito P450 enzyme models suggests 23 
that a lack of capability to metabolism pyrethroids is associated with a SRS1 arginine (R114) 24 
that projects into the access channel to restrict substrate ingress (Lertkiatmongkol et al., 2011). 25 
The equivalent SRS1 residue – D111, H111 or G111 (numbered according to the CYP6AE11 26 
sequence) – in the four H. armigera enzymes of this study have comparatively smaller side 27 
chains than arginine and therefore may not present comparable steric hindrance to substrate 28 
entry. Instead a change to the shape, flexibility or hydrophobicity of the active site may account 29 
for the effect of the SRS1 or SRS6 exchange. For example, an aromatic residue F496 on the 30 
 11 
SRS6 of CYP6AE11 and CYP6AE20 (but not present in CYP6AE17 or CYP6AE18) occupies 1 
space near the heme group and may obstruct approach of the substrate. It was proposed that a 2 
phenylalanine in the equivalent position in CYP9Q2 enzyme (F491) was a binding contact for 3 
tau-fluvalinate (Mao et al., 2007). Future mutagenesis studies can reveal the degree to which 4 
size or the presence of an aromatic ring at this position impacts enzyme reactivity. Similarly, 5 
we have identified other active site residues that merit investigation of physicochemical 6 
properties including the SRS1 residue at position 112. This residue is positively-charged in 7 
CYP6AE11, CYP6AE17 and CYP6AE18 and may form electrostatic interactions with 8 
electronegative groups on the pyrethroid and consequently help orientate the substrate for 9 
reaction. In CYP6AE20 this position is occupied by a small polar residue (S112) and this may 10 
be a contributing factor for the inactivity of CYP6AE20 towards esfenvalerate in contrast to the 11 
metabolic capability of the CYP6AE20-11SRS1 chimera. 12 
The multiple duplications of P450 genes leading to CYP blooms (Feyereisen, 2011) can 13 
result in versatile and enhanced detoxification capacities. The accumulated variation within 14 
SRSs of duplicated alleles (Zimmer et al., 2018) or paralogs (Mao et al., 2009, 2011; Shi et al., 15 
2018; Li et al., 2003; Manjon et al., 2018; Troczka et al., 2019) is associated with novel 16 
functions or with higher detoxification capability to certain compounds. As most CYP6AE 17 
P450s in H. armigera can metabolize esfenvalerate with different efficiencies and are easily 18 
induced by xenobiotics (Shi et al., 2018; Wang et al., 2018), it is possible that certain field 19 
strains could gain resistance to fenvalerate rapidly by selection of CYP6AE variants that are 20 
easily induced, constitutively overexpressed or with higher metabolic efficiency, or indeed with 21 
a combination of such traits. In this sense, the structure-derived functional divergence among 22 
members of a CYP cluster may contribute to the development of insecticide resistance.  23 
In summary, a clustered P450 subfamily such as the CYP6AE, with high sequence identity 24 
and known catalytic capacity constitutes a great material to study the structure-based functional 25 
diversity and evolution of insect P450s. Our findings not only identified molecular determinants 26 
of the dramatic difference in esfenvalerate metabolism between H. armigera CYP6AE P450s, 27 
but also provide a basis for further research on the functional divergence of this subfamily and 28 
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Figure 1. Primary sequences of four CYP6AE proteins. Four conserved motifs: WxxxR 
motif, ExxRxxP motif, PxRF motif and Heme binding site are underlined. The six SRS 




Figure 2. Construction of CYP6AE mutants. A: Typical structure of microsomal P450 protein, 
SRS, SAD (membrane-embedded signal anchor domain) and five conserved regions of 
microsomal P450 (WxxxR motif, A(A,G)x(E,Q)T motif, ExxRxxP motif, PxRF motif and 
Heme binding site) were marked. B: SRS1 exchanging of CYP6AE11/20; C: SRS1/SRS6 





Figure 3. Identification of recombinant P450 mutants. A. Western Blot. 20μg purified 
microsomal protein with co-expressed P450 and HaCPR was loaded for each sample. B. 
Reduced CO-difference spectra of heterologously expressed CYP6AE hybrid mutants. Sf9 cells 




Figure 4. Qualitative enzyme activity tests toward esfenvalerate with six CYP6AE P450 







Figure 5. P450 homology models and docking predictions for esfenvalerate. A: sequence 
alignment of SRS1 and SRS6 sections. Residues highlighted in purple are predicted to line the 
active site of each enzyme (see B) and are numbered according to the 6AE11 sequence 
(GenBank: AEY75583.1). B: Left panels show the volume of each active site cavity depicted 
in green. The SRS1, 2, 3, 5 and 6 sections are shown in semi-transparent surface; SRS4 is not 
shown to aid visualisation. SRS1 and SRS6 sections are additionally shown as ribbon. SRS1 
and SRS6 residues lining the cavity are in purple sticks. The heme group is in grey space-fill. 
Right panels show docked poses of esfenvalerate as yellow sticks. SRS1 and SRS6 residues 














CYP6AE11b 2.3±0.1 5.9±0.7 0.39 
CYP6AE11-20SRS1 24.7±2.5c 6.6±1.7 - 
CYP6AE20 n.d.d n.d. n.d. 
CYP6AE20-11SRS1 0.17±0.001 3.7±0.6 0.05 
CYP6AE17b 1.5±0.04 5.5±0.4 0.27 
CYP6AE17-18SRS1 0.19±0.01 8.3±1.6 0.02 
CYP6AE17-18SRS6 1.7±0.11 11.4±1.9 0.15 
CYP6AE18b 0.1±0.01 2.8±0.5 0.04 
CYP6AE18-17SRS1 1.5±0.1 6.0±1.2 0.25 
CYP6AE18-17SRS6 0.72±0.05 1.8±0.5 0.4 
a Intrinsic clearance. 
b Data from Shi et al. (2018). 
c pmol/min/mg protein. 
d Not detected.  
 
